Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Earnings for Prelude Therapeutics Incorporated (PRLD)
Earnings in 2023 (TTM): $-121,832,000
According to Prelude Therapeutics Incorporated's latest financial reports the company's current earnings (TTM) are $-121,832,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Prelude Therapeutics Incorporated
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-121,832,000 | $-121,832,000 |
| 2022 | $-115,438,000 | $-107,336,000 |
| 2021 | $-111,694,000 | $-110,779,000 |
| 2020 | $-56,929,000 | $-56,929,000 |
| 2019 | $-27,570,000 | $-27,570,000 |
| 2018 | $-14,680,000 | $-14,680,000 |